HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Primo N Lara Selected Research

Thrombocytopenia chromosome breakage

11/2019First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors.
6/2010Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Primo N Lara Research Topics

Disease

99Neoplasms (Cancer)
01/2022 - 02/2002
59Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
11/2021 - 02/2002
39Prostatic Neoplasms (Prostate Cancer)
10/2022 - 06/2003
21Renal Cell Carcinoma (Grawitz Tumor)
01/2021 - 02/2003
18Neoplasm Metastasis (Metastasis)
01/2021 - 02/2002
18Small Cell Lung Carcinoma (Small Cell Lung Cancer)
11/2016 - 07/2003
15Lung Neoplasms (Lung Cancer)
10/2019 - 08/2003
11Carcinoma (Carcinomatosis)
10/2021 - 05/2002
7Disease Progression
03/2020 - 06/2007
7Pain (Aches)
08/2013 - 10/2004
6Diarrhea
11/2021 - 07/2005
6Neutropenia
10/2021 - 05/2003
6Urinary Bladder Neoplasms (Bladder Cancer)
01/2021 - 06/2009
6Breast Neoplasms (Breast Cancer)
10/2019 - 05/2002
5Fatigue
11/2019 - 08/2007
5Hypoxia (Hypoxemia)
01/2012 - 02/2002
4Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2021 - 03/2009
4Nausea
11/2019 - 10/2004
3Thrombocytopenia (Thrombopenia)
10/2021 - 01/2003
3Transitional Cell Carcinoma
01/2021 - 01/2004
3Anemia
11/2019 - 08/2007
3Carcinogenesis
01/2019 - 01/2017
2Sepsis (Septicemia)
01/2022 - 06/2005
2Circulating Neoplastic Cells
01/2021 - 01/2021
2Osteosarcoma (Osteogenic Sarcoma)
01/2021 - 05/2017
2Brain Neoplasms (Brain Tumor)
03/2020 - 01/2011
2Thrombocytopenia chromosome breakage
11/2019 - 06/2010
2Melanoma (Melanoma, Malignant)
11/2018 - 04/2012

Drug/Important Bio-Agent (IBA)

22Docetaxel (Taxotere)FDA Link
12/2018 - 05/2002
20ErbB Receptors (EGF Receptor)IBA
01/2021 - 03/2004
20PlatinumIBA
12/2018 - 02/2002
18Erlotinib Hydrochloride (CP 358,774)FDA Link
11/2021 - 08/2007
17Tyrosine Kinase InhibitorsIBA
01/2021 - 05/2006
15AndrogensIBA
10/2022 - 06/2003
13Biomarkers (Surrogate Marker)IBA
01/2021 - 04/2006
13Carboplatin (JM8)FDA LinkGeneric
03/2016 - 10/2003
12GemcitabineFDA Link
10/2021 - 01/2003
12Paclitaxel (Taxol)FDA LinkGeneric
03/2016 - 09/2002
12Bortezomib (Velcade)FDA Link
10/2011 - 08/2003
11Hormones (Hormone)IBA
10/2022 - 05/2002
11Proteins (Proteins, Gene)FDA Link
01/2022 - 01/2003
11Pharmaceutical PreparationsIBA
03/2020 - 12/2004
10Cisplatin (Platino)FDA LinkGeneric
10/2021 - 04/2003
8taxaneIBA
01/2022 - 04/2003
7Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
02/2019 - 10/2003
7Prostate-Specific Antigen (Semenogelase)IBA
12/2017 - 04/2006
7Monoclonal AntibodiesIBA
06/2010 - 05/2002
6DNA (Deoxyribonucleic Acid)IBA
01/2020 - 03/2004
6Phosphotransferases (Kinase)IBA
11/2015 - 06/2005
6Proteasome InhibitorsIBA
01/2011 - 08/2003
6Etoposide (VP 16)FDA LinkGeneric
12/2010 - 03/2006
6Trastuzumab (Herceptin)FDA Link
06/2007 - 05/2002
5Prednisone (Sone)FDA LinkGeneric
01/2021 - 10/2004
5TOR Serine-Threonine KinasesIBA
01/2021 - 01/2012
5Androgen Receptors (Androgen Receptor)IBA
01/2021 - 10/2007
5cabozantinibIBA
01/2021 - 02/2013
5Sorafenib (BAY 43-9006)FDA Link
02/2019 - 08/2007
5Biological ProductsIBA
01/2018 - 10/2003
5Irinotecan (Camptosar)FDA LinkGeneric
12/2010 - 03/2004
5Tirapazamine (SR 4233)IBA
06/2009 - 02/2002
4CreatinineIBA
10/2019 - 06/2005
4Pemetrexed (MTA)FDA Link
01/2017 - 12/2007
4ParaffinIBA
05/2013 - 05/2002
4InterferonsIBA
06/2012 - 02/2003
3RNA (Ribonucleic Acid)IBA
12/2020 - 05/2013
3Interleukin-2 (IL2)IBA
11/2018 - 02/2003
3CytokinesIBA
11/2018 - 06/2012
3afliberceptIBA
11/2018 - 10/2010
3Cytostatic AgentsIBA
10/2015 - 05/2006
3LigandsIBA
10/2015 - 01/2012
3Peptides (Polypeptides)IBA
09/2012 - 09/2003
37-hydroxystaurosporine (UCN 01)IBA
04/2012 - 04/2003
3saracatinibIBA
04/2009 - 04/2008
3EstramustineFDA Link
06/2006 - 10/2004
3Mitoxantrone (Novantrone)FDA LinkGeneric
06/2006 - 10/2004
3TubulinIBA
12/2005 - 04/2003
3Cyclin-Dependent Kinases (cdk Proteins)IBA
07/2005 - 02/2004
2bicalutamide (Casodex)FDA LinkGeneric
10/2022 - 01/2016
2Poly(ADP-ribose) Polymerase InhibitorsIBA
01/2022 - 01/2020
2Sunitinib (Sutent)FDA Link
01/2021 - 02/2019
2capmatinibIBA
01/2021 - 05/2017
2Aspartate Aminotransferases (Aspartate Transaminase)IBA
11/2019 - 06/2010
2Immune Checkpoint InhibitorsIBA
11/2019 - 11/2016
2Bevacizumab (Avastin)FDA Link
02/2019 - 12/2017
2pazopanibFDA Link
02/2019 - 07/2013
2Lipase (Acid Lipase)FDA Link
01/2019 - 01/2009
2Protein Kinases (Protein Kinase)IBA
05/2017 - 03/2009
2AtrasentanIBA
01/2017 - 08/2013
2MK 2206IBA
10/2015 - 04/2015
2tyrosine receptor (receptor, tyrosine)IBA
04/2015 - 01/2012

Therapy/Procedure

75Therapeutics
10/2022 - 02/2002
50Drug Therapy (Chemotherapy)
12/2018 - 02/2002
16Castration
01/2022 - 02/2007
8Radiotherapy
01/2017 - 02/2002
5Nephrectomy
03/2020 - 02/2009
4Immunotherapy
01/2021 - 02/2003
4Prostatectomy (Retropubic Prostatectomy)
11/2019 - 12/2007
4Combined Modality Therapy
12/2005 - 05/2002
3Chemoradiotherapy
06/2009 - 05/2002
2Intravenous Infusions
06/2015 - 07/2013